AVENTIS
Form 425
June 04, 2004

Filed by Sanofi-Synthelabo
Pursuant to Rule 165 and Rule 425(a) under the
United States Securities Act of 1933,
as amended

Subject Company: Aventis
Commission File No. 001-10378
Date: June 4, 2004

On June 4, 2004, Sanofi-Synthelabo issued the following press release.

In connection with the proposed acquisition of Aventis, Sanofi-Synthelabo has filed with the United States Securities and Exchange Commission (SEC), a registration statement on Form F-4 (File no: 333-112314), which includes a prospectus and a prospectus supplement relating to the revised offer, and related exchange offer materials, to register the Sanofi-Synthelabo ordinary shares (including Sanofi-Synthelabo ordinary shares represented by Sanofi-Synthelabo ADSs) to be issued in exchange for Aventis ordinary shares held by holders located in the United States and for Aventis ADSs held by holders wherever located and has also filed with the SEC a Statement on Schedule TO. INVESTORS AND HOLDERS OF AVENTIS SECURITIES ARE STRONGLY ADVISED TO READ THE REGISTRATION STATEMENT AND THE PROSPECTUS AND PROSPECTUS SUPPLEMENT RELATING TO THE REVISED OFFER, THE STATEMENT ON SCHEDULE TO, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS AND SUPPLEMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and holders of Aventis securities may obtain free copies of the registration statement, the prospectus, the prospectus supplement relating to the revised offer and related exchange offer materials, and the Statement on Schedule TO, as well as other relevant documents filed with the SEC, at the SEC's web site at www.sec.gov. The prospectus, the prospectus supplement relating to the revised offer and other transaction-related documents are being mailed to Aventis securityholders eligible to participate in the U.S. offer and additional copies may be obtained for free from MacKenzie Partners, Inc., the information agent for the U.S. offer, at the following address: 105, Madison Avenue, New York, New York 10016; telephone 1-(212) 929-5500 (call collect) or 1-(800) 322-2885 (toll-free call); e-mail proxy@mackenziepartners.com.

* * * *

[SANOFI-SYNTHELABO LOGO]

[GRAPHIC] INVESTOR RELATIONS

Paris, June 4, 2004

NEW INDICATIONS FOR ARIXTRA(R) IN THE UNITED STATES:
THE TREATMENT OF ACUTE DEEP VENOUS THROMBOSIS
AND ACUTE PULMONARY EMBOLISM.

Sanofi-Synthelabo announced today that the synthetic, selective factor Xa

inhibitor Arixtra(R) (fondaparinux sodium) has been approved by the US Food and Drug Administration (FDA) for two new indications:

- THE TREATMENT OF ACUTE DEEP VENOUS THROMBOSIS WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM, AND

- THE TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM WHEN INITIAL THERAPY IS ADMINISTERED IN THE HOSPITAL.

Arixtra(R) is already indicated in the United-States for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture surgery, including extended prophylaxis, hip replacement surgery and knee replacement surgery.

The file for the new indications for Arixtra(R) was submitted to the FDA July 31, 2003. The clinical dossier was based upon the findings of the MATISSE PE and MATISSE DVT studies which demonstrated that a new strength of Arixtra(R) 7.5 mg* given as a once daily subcutaneous injection, when administered in conjunction with warfarin sodium, can effectively and safely treat the acute phases of both deep vein thrombosis and pulmonary embolism.
Arixtra(R) is the first antithrombotic agent to be registered in the US specifically for the treatment of acute PE since the introduction of unfractionated heparin (UFH).

The MATISSE PE study is the largest worldwide trial ever performed in the treatment of pulmonary embolism. This open label trial involved 2,213 patients with symptomatic PE enrolled in 214 centres in 20 countries worldwide, including 67 centres in the US. The study showed that a fixed once daily subcutaneous dose of Arixtra(R) 7.5mg*, without need for coagulation monitoring, appears to be at least as effective and as safe as continuous intravenous and dose-adjusted UFH. Moreover, in the study, 15% of patients, (26.4% in the US**), received Arixtra(R) on an outpatient basis, after receiving the first dose in the hospital, compared to none with UFH.

The MATISSE DVT trial involved 2,205 patients in 23 countries in a total of 154 centers around the world with symptomatic DVT without symptomatic PE. The study showed that Arixtra(R) 7.5mg*, given once daily in a fixed subcutaneous dose appears to be at least as effective and safe as dose-adjusted low molecular weight heparin (LMWH) administered subcutaneously twice a day.

DVT and PE represent two manifestations of the same disease known as Venous Thromboembolism (VTE), a condition in which blood clots in the lower limbs (DVT) may travel to the lungs where they can cause a PE. VTE is the third most common cardiovascular disease after heart attack and stroke. VTE affects about two million Americans annually, at least 60,000 of whom will die of PE. VTE represents an annual cost of at least $2.9 billion in the US alone.

As with other antithrombotics, the most common side effect during Arixtra(R) administration is bleeding. Arixtra(R) is contraindicated in patients with severely impaired kidney function. Arixtra(R) prophylactic therapy is contraindicated in patients who weigh less than 50 kg (110 pounds), undergoing hip fracture, hip replacement and knee replacement surgery because they may have an increased risk for major bleeding. Patients greater than 75 years of age also may be more likely to experience major bleeding complications. As with other antithrombotics, labeling for Arixtra(R) includes a Boxed Warning regarding possible spinal/epidural haematomas when spinal anaesthesia or spinal puncture is used.

Arixtra(R) was launched in the United States on February 8, 2002, and in Europe as from March 27, 2002.

On April 13, 2004, Sanofi-Synthelabo signed an agreement with GlaxoSmithKline Group (GSK) regarding the divestment by Sanofi-Synthelabo, on a worldwide basis, of Arixtra(R), Fraxiparine(R) and related assets including the manufacturing facility located in Notre-Dame de Bondeville, France. The deal is conditional on completion of Sanofi-Synthelabo's offer for Aventis.

*5mg in patients with a body weight